RedHill Biopharma (ADR)
Specialty biopharmaceutical developer behind Talicia and a partner-led oral-medicine pipeline.
Something off on this page? Send us feedback.
Profile
Develops and licenses specialty biopharmaceutical medicines, with Talicia—an oral treatment for adult H. pylori infection—its only approved and revenue-producing product. Revenue also depends on Talicia joint-venture economics, territorial licensing, and potential milestones and royalties from development assets.
Develops and licenses oral small-molecule medicines for gastrointestinal disease, infectious disease, oncology and medical countermeasures. Talicia, an all-in-one oral treatment for H. pylori infection in adults, is its only FDA-approved and revenue-producing medicine; opaganib, RHB-204, RHB-102 and RHB-107 remain in development.
Operates through Tel Aviv corporate functions and a U.S. commercial base in Raleigh, with partner-led activity in the United States, Middle East and other licensed markets. Its model combines acquired or in-licensed formulations, an FDA approval pathway for certain reformulated drugs, territorial licensing and shared commercialization costs.
Holds a majority equity-method interest in Talicia Holdings, which jointly commercializes Talicia in the United States with Cumberland Pharmaceuticals. Equal board representation and joint approval rights mean key Talicia strategy is not under unilateral control.
Company facts
Key statistics
Analysts
No analyst consensus on record.
Earnings
EPSReportedEstimate
RevenueReportedEstimate
Financials
Balance sheet, Dec 31, 2025Cash & short-term investments $4.0M · Total debt $1.1M · Total assets $25.3M · Shareholders' equity $4.3M
- Revenue
- $2.0M
- Operating income
- −$2.2M
- Net income
- −$2.1M
Dividends
No dividends on record.
Ownership
3.14M ADS as of Aug 22, 2026 · holders as of their latest filing
The share count is from the company's Dec 2023 annual report; nothing newer is on file here.
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Alumni Capital LPInstitution | 11.75% | 369,373 | 13Gfiled Oct 20, 2025 ↗ |
683 Capital Management, LLCInstitution | —3.60% of class, as filed | — | 13G/Afiled Feb 13, 2020 ↗ |
Dror Ben-Asher1Insiderdirector, officer: Chief Executive Officer | — | — | Form 4filed Mar 18, 2026 ↗ |
Shmuel Cabilly1Insiderdirector | — | — | Form 4filed Mar 18, 2026 ↗ |
Cosmo Technologies Ltd.Strategic | —13.20% of class, as filed | — | 13Gfiled Mar 7, 2022 ↗ |
| See all 23 → | |||
- This position is filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 10, 2026 | Gilead Raday | officer: Chief Operating Officer | −14,130,000 | $0.0001 |
| Apr 6, 2026 | Gilead Raday | officer: Chief Operating Officer | −15,740,000 | $0.0001 |
Peers
- Phathom Pharmaceuticals
H. pylori combination regimens contest U.S. GI prescribers.
- AbbVie
Crohn’s therapies challenge a MAP-targeted development program.
- Johnson & Johnson
TREMFYA and STELARA raise the Crohn’s treatment bar.
- Takeda (ADR)
ENTYVIO is an established Crohn’s treatment alternative.
- Eli Lilly
Omvoh adds a branded IL-23 option in Crohn’s disease.
- Insmed
ARIKAYCE anchors the NTM/MAC lung-disease treatment field.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| RedHill Biopharma (ADR) | $0.8237 | −9.67% | $2.8M | — | — | 0.7 | — |
| Phathom Pharmaceuticals | $9.45 | −1.20% | $774.2M | — | 39.9 | 3.2 | +88.0% |
| AbbVie | $258.29 | +0.71% | $452.97B | 72.2 | 16.9 | 7.0 | +10.2% |
| Johnson & Johnson | $265.00 | −0.32% | $640.67B | 30.8 | 22.3 | 6.5 | +6.6% |
| Takeda (ADR) | $17.77 | −1.25% | $57.21B | 50.9 | 53.5 | 2.0 | +5.8% |
| Eli Lilly | $1,156.01 | −0.16% | $1.09T | 38.9 | 28.3 | 13.7 | +47.7% |
| Insmed | $121.79 | +2.74% | $26.40B | — | — | 23.2 | +296.1% |
| Median | 44.9 | 28.3 | 6.8 | +28.9% |